Skip to main content
Premium Trial:

Request an Annual Quote

Johnson Chiang, Rixun Fang

Johnson Chiang has been appointed chief technology officer and Rixun Fang director of assay development at Alveo Technologies.

Chiang was previously head of systems integration and molecular biology at Foundation Medicine. He also held senior management positions at Life Technologies and at Thermo Fisher Scientific. Prior to that, he led molecular diagnostic product development projects at Applied MEMS, Applied Biosystems, and Cepheid.

Fang previously led several molecular biology research and IVD development projects at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.